Identification, Isolation and Structure Confirmation of Forced Degradation Products of Sofosbuvir
- 1 Department of Chemistry, University College of Science, Osmania University, Hyderabad, Telangana, India
- 2 Department of Chemistry, University College of Science, Osmania University, Hyderabad, Telangana, India
- 3 GVK Bio Sciences Pvt. Ltd., Hyderabad, Telangana, India
- 4 Department of Chemistry, University College of Science, Osmania University, Hyderabad, Telangana, India
Abstract
A new stability indicating reverse phase chromatographic method was developed for the analysis of Heptisis C Drug Sofosbuvir. The developed UPLC method was superior in technology to conventional RP-HPLC with respect to resolution, speed, solvent consumption and analysis cost. Sofosbuvir was subjected to the thermal, hydrolytic, oxidative, and photolytic degradation, according to ICH guidelines. The drug depicted degradation in acidic, basic and oxidative conditions and it was stable to other stress conditions (thermal and photolytic). Identified degradation products were isolated using mass supported auto purification system and characterized by NMR techniques ( 1 H NMR, D 2 O Exchange, 13 C NMR, 31 P NMR, 19 F NMR, HSQC and HMBC) and HRMS experiments. Isolated acid degradation impurity was showing molecular weight of 416.08, molecular formula C 16 H 18 FN 2 O 8 P and its name as (R)-((2R, 3R, 4R, 5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methyl phenyl hydrogen phosphate. Isolated base degradation impurity-A was showing molecular weight of 453.13, molecular formula C 16 H 25 FN 3 O 9 P and its name as (S)-isopropyl 2-((R)-(((2R, 3R, 4R, 5R)-5-(2, 4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(hydroxy)phosphorylamino)propanoate. Isolated base degradation impurity-B was showing molecular weight of 411.08, molecular formula C 13 H 19 FN 3 O 9 P and its name as (S)-2-((R)-(((2R, 3R, 4R, 5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methox-y)(hydroxy)phos-phorylamino)propanoic acid. In oxidative degradation study, degradation was observed very less and with obtained quantity (less than 2 mg) recorded 1 H NMR and HRMS analysis. From the spectral data degradation product was showing molecular weight of 527.15, molecular formula C 22 H 27 FN 3 O 9 P and its name as (S)-isopropyl 2-((S)-(((2R, 4S, 5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-4-methyl-3-oxotetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate. The developed chromatographic method was validated as per ICH guidelines and proved suitable for the stability testing and quality control of the drug Sofosbuvir
- www.drugbank.ca/drugs/DB008934
- Keating, G.M. and Vaidya, A. (2014) Sofosbuvir: First Global Approval. Drugs, 74, 273-282. http://dx.doi.org/10.1007/s40265-014-0179-7
- Sofosbuvir Full Prescribing Information (2014). www.Gilead.com
- Herbst Jr, D.A. and Reddy, K.R. (2013) Sofosbuvir, A Nucleotide Polymerase Inhibitor, for the Treatment of Chronic Hepatitis C Virus Infection. Expert Opinion on Investigational Drugs, 22, 527-536. http://dx.doi.org/10.1517/13543784.2013.775246
- Spina, A., Eramova, I. and Lazarus, J.V. (2014) Policy Responses to Viral Hepatitis B and C among People Who Inject Drugs in Member States of the WHO European Region: A Sub-Analysis of the WHO 2013 Global Hepatitis Policy Survey. BMC Infectious Diseases, 14, 1. http://dx.doi.org/10.1186/1471-2334-14-S6-S15
- Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., Schultz, M., Davis, M.N., Kayali, Z., Reddy, K.R. and Jacobson, I.M. (2013) Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection. New England Journal of Medicine, 368, 1878-1887. http://dx.doi.org/10.1056/NEJMoa1214853
- Spradling, P.R., Rupp, L., Moorman, A.C., Lu, M., Teshale, E.H., Gordon, S.C., Nakasato, C., Boscarino, J.A., Henkle, E.M., Nerenz, D.R. and Denniston, M.M. (2012) Hepatitis B and C Virus Infection among 1.2 Million Persons with Access to Care: Factors Associated with Testing and Infection Prevalence. Clinical Infectious Diseases, 55, 1047-1055. http://dx.doi.org/10.1093/cid/cis616
- Chae, H.B., Park, S.M. and Youn, S.J. (2013) Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives. The Scientific World Journal, 2013, Article ID: 704912. http://dx.doi.org/10.1155/2013/704912
- Rezk, M.R., Basalious, E.B. and Karim, I.A. (2015) Development of a Sensitive UPLC-ESI- MS/MS Method for Quantification of Sofosbuvir and Its Metabolite, GS-331007, in Human Plasma: Application to a Bioequivalence Study. Journal of Pharmaceutical and Biomedical Analysis, 114, 97-104. http://dx.doi.org/10.1016/j.jpba.2015.05.006
- Pan, C., Chen, Y., Chen, W., Zhou, G., Jin, L., Zheng, Y., Lin, W. and Pan, Z. (2016) Simultaneous Determination of Ledipasvir, Sofosbuvir and Its Metabolite in Rat Plasma by UPLC-MS/MS and Its Application to a Pharmacokinetic Study. Journal of Chromatography B, 1008, 255-259. http://dx.doi.org/10.1016/j.jchromb.2015.11.056
- Shi, X., Zhu, D., Lou, J., Zhu, B., Hu, A.R. and Gan, D. (2015) Evaluation of a Rapid Method for the Simultaneous Quantification of Ribavirin, Sofosbuvir and Its Metabolite in Rat Plasma by UPLC-MS/MS. Journal of Chromatography B, 1002, 353-357. http://dx.doi.org/10.1016/j.jchromb.2015.08.038